

Rafael Bañares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592228/publications.pdf>

Version: 2024-02-01

86
papers

5,550
citations

126907

33
h-index

82547

72
g-index

91
all docs

91
docs citations

91
times ranked

5054
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	7.3	452
2	Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. <i>Hepatology</i> , 2002, 35, 609-615.	7.3	401
3	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet</i> , The, 2019, 393, 1597-1608.	13.7	375
4	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
5	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	3.7	284
6	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
7	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
8	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
9	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	1.3	210
10	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. <i>Hepatology</i> , 2000, 32, 471-476.	7.3	196
11	Response to steroids in <i>de novo</i> autoimmune hepatitis after liver transplantation. <i>Hepatology</i> , 2002, 35, 349-356.	7.3	164
12	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
13	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159
14	Carvedilol, a new nonselective beta-blocker with intrinsic anti-α ₁ -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. <i>Hepatology</i> , 1999, 30, 79-83.	7.3	158
15	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
16	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
17	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	121
18	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	113

#	ARTICLE	IF	CITATIONS
19	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	3.7	112
20	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	7.3	105
21	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	3.7	104
22	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	4.4	74
23	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, 76, 812-821.	3.7	59
24	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. Journal of Hepatology, 2020, 73, 1404-1414.	3.7	58
25	A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology, 2020, 72, 1924-1934.	7.3	56
26	Validation of Noninvasive Indices of Global Systolic Function in Patients With Normal and Abnormal Loading Conditions. Circulation: Cardiovascular Imaging, 2014, 7, 164-172.	2.6	55
27	Acute-on-chronic liver failure: A distinct clinical syndrome. Journal of Hepatology, 2021, 75, S27-S35.	3.7	55
28	Risk factors for developing <i>de novo</i> autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transplantation, 2009, 15, 530-539.	2.4	52
29	Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats – Improving Yield and Reproducibility. Scientific Reports, 2018, 8, 9163.	3.3	49
30	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	3.7	45
31	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology, 2017, 65, 2019-2030.	7.3	43
32	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. Journal of Infectious Diseases, 2020, 222, 726-733.	4.0	43
33	Antibodies Against Glutathione S-Transferase T1 (GSTT1) in Patients With GSTT1 Null Genotype as Prognostic Marker: Long-Term Follow-Up After Liver Transplantation. Transplantation, 2007, 83, 1126-1129.	1.0	38
34	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599.	3.7	36
35	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	3.7	28
36	Molecular Adsorbent Recirculating System and Bioartificial Devices for Liver Failure. Clinics in Liver Disease, 2014, 18, 945-956.	2.1	24

#	ARTICLE	IF	CITATIONS
37	Liver Support Systems: Will They Ever Reach Prime Time?. Current Gastroenterology Reports, 2013, 15, 312.	2.5	23
38	Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver International, 2018, 38, 102-112.	3.9	21
39	Enfermedades vasculares del h�gado. Gu�as Cl�nicas de la Sociedad Catalana de Digestolog�a y de la Asociaci�n Espa�ola para el Estudio del H�gado. Gastroenterolog�a Y Hepatolog�a, 2017, 40, 538-580.	0.5	20
40	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1627-1633.	2.8	19
41	A new role for reticulon-4B/NOGO-B in the intestinal epithelial barrier function and inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2015, 308, G981-G993.	3.4	17
42	Intestinal Epithelial Cell-Derived Extracellular Vesicles Modulate Hepatic Injury via the Gut-Liver Axis During Acute Alcohol Injury. Frontiers in Pharmacology, 2020, 11, 603771.	3.5	17
43	Clinical Utility of a Risk�Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients. Liver Transplantation, 2019, 25, 1177-1186.	2.4	16
44	Preconditioning by portal vein embolization modulates hepatic hemodynamics and improves liver function in pigs with extended hepatectomy. Surgery, 2017, 161, 1489-1501.	1.9	15
45	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. Cancers, 2022, 14, 192.	3.7	15
46	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatology Communications, 2021, 5, 309-322.	4.3	13
47	Enfermedad hep�tica por alcohol. Gu�as de pr�ctica cl�nica. Documento de consenso auspiciado por la AEEH. Gastroenterolog�a Y Hepatolog�a, 2019, 42, 657-676.	0.5	12
48	Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real�life study. European Journal of Neurology, 2022, 29, 400-412.	3.3	12
49	Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?. World Journal of Gastroenterology, 2021, 27, 6737-6749.	3.3	11
50	Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver International, 2016, 36, 232-239.	3.9	10
51	Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986215.	3.2	10
52	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. Liver International, 2020, 40, 646-653.	3.9	10
53	Long�term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. Liver International, 2019, 39, 45-48.	3.9	9
54	Decreased Long�Term Severe Acute Respiratory Syndrome Coronavirus 2�Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. Liver Transplantation, 2022, 28, 1039-1050.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Cardiac function, A key component in evaluation for liver transplant. Liver Transplantation, 2018, 24, 7-8.	2.4	8
56	Endoscopically placed stents: a useful alternative for the management of refractory benign cervical esophageal stenosis. Revista Espanola De Enfermedades Digestivas, 2017, 109, 510-515.	0.3	8
57	De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S-transferase theta 1. Liver Transplantation, 2017, 23, 75-85.	2.4	7
58	Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110234.	3.2	7
59	Acute liver failure caused by mushroom poisoning: still a fork in the road. Liver International, 2016, 36, 952-953.	3.9	6
60	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transplant International, 2017, 30, 1041-1050.	1.6	6
61	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therapeutic Advances in Gastroenterology, 2019, 12, 1756284819879565.	3.2	6
62	Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via ABCA1 and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1661-1673.	1.9	5
63	Portal stenosis in liver transplantation. Treatment by endoluminal prosthesis. Transplant International, 1995, 8, 74-75.	1.6	4
64	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. Open Forum Infectious Diseases, 2019, 6, ofz214.	0.9	4
65	Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). Biomedicines, 2021, 9, 1289.	3.2	4
66	International multicenter validation of <scp>GES</scp> score for <scp>HCC</scp> risk stratification in chronic hepatitis C patients. Journal of Viral Hepatitis, 2022, 29, 807-816.	2.0	4
67	Intraoperative Troponin Elevation in Liver Transplantation Is Independently Associated With Mortality: A Prospective Observational Study. Liver Transplantation, 2020, 26, 681-692.	2.4	3
68	Portal stenosis in liver transplantation. Treatment by endoluminal prosthesis. Transplant International, 1995, 8, 74-75.	1.6	3
69	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología Y Hepatología, 2022, 45, 724-734.	0.5	3
70	Pressure volume curves in cirrhosis: More than meets the eye. Journal of Hepatology, 2017, 67, 656-657.	3.7	2
71	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. Revista Espanola De Enfermedades Digestivas, 2020, 112, 778-783.	0.3	2
72	A new pattern in hepatitis A virus infection in an urban population. Revista Espanola De Enfermedades Digestivas, 2020, 112, 178-182.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study. Liver Transplantation, 2022, 28, 1257-1261.	2.4	2
74	A gut solution for hepatic encephalopathy. Hepatology, 2015, 61, 2107-2009.	7.3	1
75	Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation. Therapeutic Apheresis and Dialysis, 2016, 20, 189-196.	0.9	1
76	It takes two "eyes" to see in depth. Journal of Hepatology, 2019, 70, 790-791.	3.7	1
77	Reply to: "Beta-blockers in refractory ascites" is it truly the end of the road? Journal of Hepatology, 2020, 73, 1291-1292.	3.7	1
78	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e587-e593.	1.6	1
79	Familial low phospholipid-associated cholelithiasis resulting from an autosomal dominant ABCB4 mutation. Revista Espanola De Enfermedades Digestivas, 2019, 111, 806-808.	0.3	1
80	Fully covered metal stent placement as first-line endoscopic treatment for complicated portal cavernoma cholangiopathy. Liver International, 2022, 42, 710-713.	3.9	1
81	Reply:. Hepatology, 2002, 36, 1024-1025.	7.3	0
82	Early transplanted liver performance and indocyanine green clearance. Liver Transplantation, 2010, 16, n/a-n/a.	2.4	0
83	Acute on chronic liver failure: Are we ready to predict?. Liver International, 2017, 37, 1449-1450.	3.9	0
84	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?" Journal of Hepatology, 2020, 73, 977-979.	3.7	0
85	Reply to: "Open or closed window: That is the question" Journal of Hepatology, 2021, 74, 486-487.	3.7	0
86	ESOPHAGOGASTRIC VARICEAL BLEEDING AS DEBUT OF CAROLI'S SYNDROME: A REPORTED CASE. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	0